Business
Parsortix Manufacturer Appointed
Parsortix Manufacturer Appointed.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 6086F Angle PLC 28 May 2013 \n \n\n\n\n\n\nFor immediate release \n \n\n\n28 May 2013\n\n\n\n\n \nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nPARSORTIX MANUFACTURER APPOINTED \n \nANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that the Company has appointed a manufacturer for its Parsortix non-invasive cancer diagnostic product. \n \nFollowing a thorough selection process, ANGLE has selected Cogent Technology Limited (\"Cogent\") to manufacture the Parsortix automated machine. The consumable for the system, the Parsortix cassette, will continue to be produced by specialist nano-manufacturer thinXXS.\n \nThe Parsortix automated machine can be configured either for the counting and identification of circulating tumour cells (CTCs) in the blood, or for the capture and harvesting of the CTCs from the blood for further molecular analysis.\n \nThe appointment of Cogent enables ANGLE to increase manufacturing volumes to meet expected demand, initially for the research market and then for the clinical market. Cogent will provide robust manufacturing services and supply chain management in accordance with the necessary quality assurance methods for electro-mechanical products destined for critical markets such as healthcare. \n \nThe Company's out-sourcing strategy continues to be the best way to deliver the roll out of Parsortix, without the associated investment and running costs of undertaking these activities in house.\n \n \nANGLE's Founder and Chief Executive, Andrew Newland, commented:\n\"The appointment of a specialist, larger scale manufacturer with the necessary quality systems to support regulatory authorisation is an important step towards positioning ANGLE so that it is capable of meeting substantial market demand in the future. We have already initiated the roll out of Parsortix into the research market and look forward to continuing the roll out into the clinical market once regulatory authorisations have been received.\" \n \n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n01483 685830\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n\nCenkos Securities\nAdrian Hargrave, Stephen Keys (Nominated ...